Navigation Links
Virus May Check Spread Of Bird Flu

According to researchers at Purdue University and the Centers for Disease Control and Prevention, virus may be used to check the spread of bird flu in human beings.

Purdue molecular virologists are investigating // a new way to provide immunity against avian influenza viruses, or bird flu, the most lethal of which, H5N1, has a 50 percent fatality rate in humans. The researchers are focusing on using a harmless virus, called adenovirus, as a transmitting agent for a vaccine to fight off highly virulent strains of the avian influenza viruses.

Current vaccines are designed for strains of flu found in local areas and are effective only as long as the virus doesn't change form. Existing vaccines will have limited success against new strains of avian influenza, he said. Every time bird flu mutates, vaccines must be redesigned.

An additional important advantage to using an adenovirus as a vector, or transporter of vaccine into cells, is that is could be mass-produced much more quickly than with current methods.

Even with a recently developed vaccine based on growing a single protein of H5N1, it would be difficult to rapidly produce enough protective medication to stem a pandemic, according to experts from the CDC, World Health Organization and NIAID. However, a large quantity of an adenovirus-based vaccine could easily be produced on short notice, said the researchers.

Source: Newswise
'"/>




Page: 1

Related medicine news :

1. Virus Level could Predict Cervical Cancer Risk
2. Ebola Virus - Outbreak Claims More Lives In Uganda.
3. Experimental treatment for Ebola Virus Shows promising results in mice
4. Virus Combats Brain Tumour
5. Virus killer
6. Pain Killers Keep the Virus Away
7. Measles Suppresses AIDS Virus
8. Virus connection to cervical injury
9. Virus Helps Remove Brain Cancer
10. Origin Of SARS Virus Discovered
11. New Molecule that can stop the growth of Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Virus May Check Spread Bird Flu

(Date:7/18/2008)...hical issues facing medical physicists are numerou...reas of medicine. Certain activities, such as hand...y the federal and state governments. Other activit...rds and licensure requirements vary from state to ...l help dissect these ethical and regulatory issues...
(Date:7/18/2008)...ire-FirstCall/ -- SyntheMed, Inc. (OTC,Bulletin Bo...development,and commercialization of anti-adhesion...ts, announced today the appointment of Ms. Corinne... International Market Development.,Ms. Mundin, who... sales,sales management and market development ex...
(Date:7/18/2008)...hen Existing Therapeutic Focus Through ...UTH MEETING, Pa., July 18 /Xinhua-PRNewswire-First...BMP Sunstone"; the "Company") today,announced that...Pharmaceutical Co., Ltd. ("Sunstone") has signed a...t of Zhangjiakou Shengda Pharmaceutical Co., Ltd,(...
(Date:7/18/2008)...long-term care software companies offer seamless d...ems. , Indianapolis, IN (...of Clinical Management Software for the long term ...ional provider of patient referral software to the...p to help long term care facilities efficiently ma...
Breaking Medicine News(10 mins):Health News:Legal and ethical issues in medical physics 2Health News:Legal and ethical issues in medical physics 3Health News:Legal and ethical issues in medical physics 4Health News:Legal and ethical issues in medical physics 5Health News:Legal and ethical issues in medical physics 6Health News:Legal and ethical issues in medical physics 7Health News:SyntheMed Appoints Corinne Mundin as Director, International Market Development 2Health News:SyntheMed Appoints Corinne Mundin as Director, International Market Development 3Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 2Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 3Health News:Qtrac Software and Patient Placement Systems Announce Partnership and Healthcare Data Interface 2Health News:Qtrac Software and Patient Placement Systems Announce Partnership and Healthcare Data Interface 3
...for resistance to food allergy has been identified...s currently no way to treat food allergy and the ... avoid certain foods and make sure they have injec...led by Dr Claudio Nicoletti at the Institute of Fo...
...ficials of DelSite Biotechnologies, Inc., a wholly... said the company's novel powder-based vaccine de...les that delay influenza pandemic preparedness whi...tions for the Control of Influenza VI Conference" ...
...nsylvania, Shire plc announced today that it has s...A) to the U.S. Food and Drug Administration (FDA) ...the treatment of Attention Deficit Hyperactivity D...cation is subject to a 10-month FDA review period....
...of Wales has proposed that artists are important t...Wales to help create better environments for pati... for all new hospital that is going to come up in ...order to ensure that the patients morale is booste...
Other Medicine News:Health News:Potential Target for Allergy Therapy 2Health News:DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations 2Health News:DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations 3Health News:VYVANSE(TM) Drug for the Treatment of ADHD in Adults 2Health News:Art in Hospitals to Enhance Patient Care 2
(Date:7/17/2008)... FREISING-WEIHENSTEPHAN and JENA, Germany, July 17...ompany developing Anticalins(R), a novel,class of ...otech GmbH, a,full-service contract manufacturer o...icant milestone in the development of Pieris, PRS-... developed PRS-050 as a next generation VEGF antag...
(Date:7/17/2008)...econd instance where survival increase is observed...receiving Tavocept in conjunction with standard ...n survival increase of 6.5 months seen for patient...pe of lung cancer, SAN ANTONIO, July 17 /PRNewswi...ik") today announced that patients with adenocarci...
(Date:7/16/2008)... DANBURY, Conn., July 16 /-...ts two pivotal Phase III VIAject(TM) clinical,tria...isit on July 14,2008. Results of the full trial w...tion at the European Association for the Study of ...at a later appropriate scientific forum., Biodel ...
(Date:7/16/2008)... Raptor to Support Phase 2a Clinical Tria...rstCall/ -- Raptor,Pharmaceuticals Corp. ("Raptor"...ay announced the execution of a collaboration agre...ifornia, San Diego ("UCSD") to,include a Phase 2a ...ration,of cysteamine bitartrate ("Cysteamine") in ...
Breaking Medicine Technology:Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050 2BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial 2BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial 3BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial 4Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program 2Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program 3Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program 4Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program 5Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance 5813 1Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance 5813 2Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance 5813 3Heart Patients More Likely to Adopt Healthy Habits in 3 Year Program Led by Cardiac Rehabilitation Experts Mayo Clinic Research Shows 2327 1Heart Patients More Likely to Adopt Healthy Habits in 3 Year Program Led by Cardiac Rehabilitation Experts Mayo Clinic Research Shows 2327 2Heart Patients More Likely to Adopt Healthy Habits in 3 Year Program Led by Cardiac Rehabilitation Experts Mayo Clinic Research Shows 2327 3Heart Patients More Likely to Adopt Healthy Habits in 3 Year Program Led by Cardiac Rehabilitation Experts Mayo Clinic Research Shows 2327 4Cooling May Not Help Injured Brains in Children 21089 1Cooling May Not Help Injured Brains in Children 21089 2Cooling May Not Help Injured Brains in Children 21089 3Verizon Executive Urges Congress to Pass Health Care IT Legislation 21084 1Verizon Executive Urges Congress to Pass Health Care IT Legislation 21084 2Verizon Executive Urges Congress to Pass Health Care IT Legislation 21084 3Verizon Executive Urges Congress to Pass Health Care IT Legislation 21084 4
... Pain on Sleep Interference, INDIANAPOLIS, May 03,... analysis of three studies suggest that in patient...abetic peripheral neuropathy,who are treated with...verage daily pain and night pain severity were ass...than in those patients,taking sugar pill. Results ...
...2007 /PRNewswire-FirstCall/ --,Phosphagenics Limit...ends to initiate a Phase 1b clinical trial to demo...rmulation of its transdermal,insulin product, TPM-...ial is expected to commence in the second quarter ...s a novel "needle-free",way of administering insul...
Other Medicine Technology:Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 2Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 3Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 4Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 5Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 6Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: